Novo Nordisk suspended from industry body over serious breaches

Novo Nordisk has been suspended from the Association of the British Pharmaceutical Industry (ABPI) for failing to disclose its sponsorship of a training course promoting its obesity drug, Saxenda. The ABPI claims Novo Nordisk paid for and “disguised” this large-scale promotional campaign.